Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone844-967-2633
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.45 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/27/2019 (Estimated)
OptionableOptionable
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
When is Oramed Pharmaceuticals' next earnings date?
What price target have analysts set for ORMP?
2 Wall Street analysts have issued twelve-month target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $13.50 in the next year. This suggests a possible upside of 329.9% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.
What is the consensus analysts' recommendation for Oramed Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.
Has Oramed Pharmaceuticals been receiving favorable news coverage?
Press coverage about ORMP stock has been trending neutral on Tuesday, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news impact score of 0.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Oramed Pharmaceuticals.
Are investors shorting Oramed Pharmaceuticals?
Oramed Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 67,000 shares, an increase of 10.6% from the August 30th total of 60,600 shares. Based on an average trading volume of 49,700 shares, the short-interest ratio is presently 1.3 days. Currently, 0.5% of the shares of the company are sold short. View Oramed Pharmaceuticals' Current Options Chain.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Albireo Pharma (ALBO), Osmotica Pharmaceuticals (OSMT), TapImmune (MRKR), Athersys (ATHX), Xeris Pharmaceuticals (XERS), NuCana (NCNA), Mirum Pharmaceuticals (MIRM), Kamada (KMDA), Spero Therapeutics (SPRO), LifeVantage (LFVN), Chiasma (CHMA), GlycoMimetics (GLYC), CV Sciences (CVSI), Kalvista Pharmaceuticals (KALV) and Mallinckrodt (MNK).
What other stocks do shareholders of Oramed Pharmaceuticals own?
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
- Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
- Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
- Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $3.14.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $54.57 million and generates $2.45 million in revenue each year. The biotechnology company earns $-12,720,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.
What is Oramed Pharmaceuticals' official website?
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is 142 WEST 57TH STREET, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
